Trademark: 79286017
Word
CELLVIE
Status
Dead
Status Code
602
Status Date
Friday, October 15, 2021
Serial Number
79286017
Mark Type
4
Filing Date
Wednesday, December 18, 2019
Abandoned Date
Thursday, September 30, 2021

Trademark Owner History
cellvie Inc. - 1st New Owner Before Publication
Cellvie UG (haftungsbeschränkt) - Original Applicant

Classifications
5 Preparations for medical purposes employing mitochondria; cardiovascular treatment preparations employing mitochondria; cardiovascular pharmaceuticals employing mitochondria used in treating arrhythmias; pharmaceutical and biological preparations for the treatment of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies, tumors or diabetes mitochondria for transplant purposes for medical use; pharmaceutical and biological preparations for the application of mitochondria transplantation for medical purposes in vessel and organ transplantations; implantable living tissue and mitochondria for the promotion of tissue growth, for medical use; mitochondria, for medical use; biological tissue cultures containing mitochondria for medical purposes; pharmaceutical and biological preparations containing mitochondria for tissue regeneration and protection for medical purposes; living cell components, namely, mitochondria, including genetically-modified mitochondria or pharmaceutically treated mitochondria, for medical use in humans and veterinary use in animals
44 Medical testing services for diagnostic and disease treatment purposes relating to cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of human or animal tissues for mitochondria transplant treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of cells and cell components in relation to mitochondria for diagnostic and treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors
10 Prosthetic tissues based on mitochondria for parietal, vascular and visceral use; medical apparatus and devices for the processing of tissue- or cell-samples for the isolation of mitochondria or other cell components, namely, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from muscle tissue or other human or animal tissues, as well as from cells and cell cultures; filter for the isolation of cell components, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from cells for medical purposes; medical apparatus and devices for the transplantation or injection of cells or cell component, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles in humans or animals
42 Scientific and technological services, namely, scientific and clinical research, analysis and testing in the field of mitochondrial isolation or transplantation; scientific and clinical research and development services in the field of mitochondria; conducting clinical trials for others in the field of cardiovascular diseases, ischemia-and reperfusion-injuries, heart transplantations, tumor treatments, mitochondrial myopathies analysis of human tissues for scientific and clinical research relating to mitochondria; scientific and clinical research, analysis and testing services relating to the isolation and cultivation of human and animal mitochondria
The wording "CELLVIE" has no meaning in a foreign language.

Trademark Events
May 21, 2020
Sn Assigned For Sect 66a Appl From Ib
May 22, 2020
New Application Office Supplied Data Entered
May 22, 2020
Assigned To Examiner
May 26, 2020
Application Filing Receipt Mailed
May 28, 2020
Non-Final Action Written
May 29, 2020
Non-Final Action (Ib Refusal) Prepared For Review
Jun 29, 2020
Refusal Processed By Mpu
Jun 29, 2020
Non-Final Action Mailed - Refusal Sent To Ib
Jul 17, 2020
Correction Transaction Received From Ib
Jul 31, 2020
Refusal Processed By Ib
Oct 16, 2020
Correction From Ib Entered - No Review Required
Dec 3, 2020
Teas Response To Office Action Received
Mar 5, 2021
Assigned To Lie
Mar 5, 2021
Correspondence Received In Law Office
Mar 5, 2021
Teas/Email Correspondence Entered
Mar 29, 2021
Final Refusal Written
Mar 29, 2021
Final Refusal E-Mailed
Mar 29, 2021
Notification Of Final Refusal Emailed
Oct 15, 2021
Abandonment - Failure To Respond Or Late Response
Oct 15, 2021
Abandonment Notice E-Mailed - Failure To Respond
Dec 22, 2021
Notification Of Possible Opposition Created, To Be Sent To Ib
Dec 22, 2021
Notification Of Possible Opposition Sent To Ib
Jan 9, 2022
Notification Of Possible Opposition - Processed By Ib
Oct 15, 2022
Final Disposition Notice Created, To Be Sent To Ib
Oct 17, 2022
Final Disposition Notice Sent To Ib
Nov 7, 2022
Final Decision Transaction Processed By Ib
Sep 20, 2024
Change Of Owner Received From Ib

Trademark Alertz updated from USPTO on 2030-01-24